Exelixis Inc - Company Profile
Powered by 
All the data and insights you need on Exelixis Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Exelixis Inc Strategy Report
- Understand Exelixis Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Exelixis Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Exelixis Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 13 Jun 2022 | Lorem |
| Exelixis close to 100-patient milestone in Phase Ib CRPC cohort aimed at garnering accelerated approval; pivotal trial to start enrolling in a few months, investigator says | 13 Feb 2020 | Reynald Castaneda |
| Exelixis’ Cabometyx plus AstraZeneca’s Imfinzi investigator-led Phase Ib trial in gastroesophageal cancer recruits more than 20 of 30-patient target; final dosing 1Q20, source says | 03 Dec 2019 | Reynald Castaneda |
| First-line HCC Phase III trials need noninferior efficacy, superior safety versus Roche’s Tecentriq/Avastin but likelihood forecasts challenging, experts say | 29 Nov 2019 | Reynald Castaneda |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer